Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross mTOR Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedPremera BluecrossPolicy N/A

    Use of mTOR Kinase Inhibitors in Cancer and Rare Diseases

    Customize your policy alerts

    Sign up for all Premera Bluecross policy alerts

    Know when Premera Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity coverage and prior-authorization requirements for oral, topical, and intravenous mTOR kinase inhibitors used for selected cancers, tuberous sclerosis complex, lymphangioleiomyomatosis, and organ-transplant rejection prophylaxis under the pharmacy or medical benefit.

    Policy Summary
    PayerPremera Bluecross
    PolicyUse of mTOR Kinase Inhibitors in Cancer and Rare Diseases
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewAug 10, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting that medical-necessity criteria are met, including the diagnosis, relevant history, physical evaluation, and medication history.
    SourceLink
    POLICY UPDATE CHANGES

    Generic Yulithira (everolimus) was added to the policy with the same coverage criteria as generic everolimus tablets.

    The initial authorization period for all other reviews of oral and topical drugs listed in the policy was changed from 3 months to 6 months.

    Metastatic endometrial carcinoma after prior therapy, with everolimus used in combination with letrozole, was added to coverage criteria.

    Non-formulary exception review authorizations for all drugs listed in the policy may be approved for up to 12 months.

    Listed medications must follow the applicable product's FDA dosage and administration instructions.

    Brand Afinitor products require a prior trial of the corresponding generic everolimus formulation.

    Generic Yulithira was added with the same coverage criteria as generic everolimus tablets.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    6 monthsInitial authorization period
    12 monthsMaximum reauthorization period with criteria and response documented
    10 mg/dayMaximum Afinitor dose for specified indications
    Pharmacy or medicalPotential benefit administration
    1New drug added in September 2026

    Covered Drugs and Indications

    Afinitor cancer and TSC indications

    Afinitor may be considered medically necessary when the individual meets one of the applicable indications and all requirements for that indication.

    ALL of the following

    • ONE covered indication

      • ALL of the following

        • Postmenopausal woman with advanced hormone receptor-positive, HER2-negative breast cancer; Afinitor is used in combination with exemestane after failure of letrozole or anastrozole.
      • ALL of the following

        • Metastatic endometrial carcinoma after prior therapy; Afinitor is used in combination with letrozole.
      • ALL of the following

        • Adult with advanced renal cell carcinoma after treatment failure with sunitinib or sorafenib.
      • ALL of the following

        • Adult with progressive, unresectable neuroendocrine tumor of pancreatic, gastrointestinal, or lung origin.
      • ALL of the following

        • Adult with renal angiomyolipoma associated with tuberous sclerosis complex that does not require immediate surgery.
      • ALL of the following

        • Adult or pediatric individual aged 1 year or older with tuberous sclerosis complex and subependymal giant cell astrocytoma requiring therapeutic intervention but not curatively resectable.Age 1 year or older
    • Additional requirements

      • The individual has tried generic everolimus tablet and had an inadequate response or intolerance.
      • The Afinitor dose is limited to 10 mg per day.10 mg/day maximum

    Afinitor Disperz for TSC

    Afinitor Disperz may be considered medically necessary when all of the following are met:

    ALL of the following

    • ONE TSC indication

      • Adult or pediatric individual aged 1 year or older with tuberous sclerosis complex and subependymal giant cell astrocytoma requiring therapeutic intervention but not curatively resectable.Age 1 year or older
      • Adult or pediatric individual aged 2 years or older with tuberous sclerosis complex-associated partial-onset seizures.Age 2 years or older
    • The individual has tried generic everolimus tablet for oral suspension and had an inadequate response or intolerance.

    Hyftor for TSC-associated facial angiofibroma

    Hyftor may be considered medically necessary when all of the following are met:

    ALL of the following

    • The individual is aged 6 years or older.Age 6 years or older
    • The individual has facial angiofibroma associated with tuberous sclerosis complex.
    • The dose is limited to the age-appropriate amount: 600 mg (2 cm) for individuals 6 through 11 years of age, or 800 mg (2.5 cm) for individuals 12 years of age or older.600 mg (2 cm) ages 6-11; 800 mg (2.5 cm) age 12 or older

    Fyarro for PEComa

    Fyarro may be considered medically necessary when the following criterion is met:

    ALL of the following

    • The individual is an adult with perivascular epithelioid cell tumor (PEComa).Adult

    Torisel for advanced RCC

    Torisel may be considered medically necessary when the following criterion is met:

    ALL of the following

    • The individual has advanced renal cell carcinoma (RCC).Advanced RCC

    Transplant rejection prophylaxis and lymphangioleiomyomatosis

    The following uses are considered medically necessary:

    ONE covered use

    • Everolimus tablet or Zortress (everolimus) for prophylaxis of organ rejection in individuals receiving allogeneic transplants.
    • Prograf (tacrolimus) for prophylaxis of organ rejection in individuals receiving allogeneic transplants.
    • ANY of the following

      • Rapamune (sirolimus) for prophylaxis of organ rejection in individuals receiving allogeneic transplants.
      • Rapamune (sirolimus) for treatment of lymphangioleiomyomatosis.

    Metastatic Endometrial Carcinoma

    Coverage includes the following metastatic endometrial carcinoma indication:

    ALL of the following

    • The individual has metastatic endometrial carcinoma.
    • The individual has received prior therapy.
    • Everolimus is used in combination with letrozole.

    Brand Everolimus Step Therapy

    Brand products require prior trial of the corresponding generic formulation:

    ONE applicable brand-product pathway

    • ALL of the following

      • Afinitor is requested.
      • The individual has tried generic everolimus tablet and had an inadequate response or intolerance.
    • ALL of the following

      • Afinitor Disperz is requested.
      • The individual has tried generic everolimus tablet for oral suspension and had an inadequate response or intolerance.

    Everolimus is not labeled for use in individuals with carcinoid tumors that actively produce hormones. The National Comprehensive Cancer Network (NCCN) assigns these tumors a Category 2A recommendation.

    Adjuvant therapy is not recommended outside a clinical trial for individuals with localized renal cell carcinoma (RCC), Stages I-III, who have undergone complete resection.

    This medical policy does not apply to Medicare Advantage.

    For localized RCC, Stages I-III, after complete resection, adjuvant therapy is not recommended outside a clinical trial. Observation remains the standard of care for this population.

    Initial Authorization Requirements

    Afinitor initial therapy

    Afinitor initial therapy may be considered when all of the following are met:

    ALL of the following

    • ONE applicable indication

      • Postmenopausal woman with advanced hormone receptor-positive, HER2-negative breast cancer; Afinitor will be used with exemestane after failure of letrozole or anastrozole.
      • Metastatic endometrial carcinoma after prior therapy; Afinitor will be used with letrozole.
      • Adult with advanced RCC after treatment failure with sunitinib or sorafenib.
      • Adult with progressive, unresectable neuroendocrine tumor of pancreatic, gastrointestinal, or lung origin.

    Reauthorization Requirements

    Continuation therapy

    Reauthorization may be considered when all of the following are met:

    ALL of the following

    • The drug-specific coverage criteria remain met.
    • Chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    Required Generic Product Trials

    StepRequested brand productRequired prior trialApplies to
    1Afinitor (everolimus tablet)Try generic everolimus tablet and document an inadequate response or intolerance.Postmenopausal advanced hormone receptor-positive, HER2-negative breast cancer; metastatic endometrial carcinoma after prior therapy; advanced RCC after failure of sunitinib or sorafenib; progressive, unresectable pancreatic, gastrointestinal, or lung NET; TSC-associated renal angiomyolipoma when immediate surgery is not required; or TSC-associated SEGA requiring therapeutic intervention but not curatively resectable.
    StepRequested brand productRequired prior trialApplies to
    1Afinitor Disperz (everolimus tablet for oral suspension)Try generic everolimus tablet for oral suspension and document an inadequate response or intolerance.TSC-associated SEGA requiring therapeutic intervention but not curatively resectable in individuals aged 1 year or older, or TSC-associated partial-onset seizures in individuals aged 2 years or older.
    Brand productCorresponding generic trial required firstFailure criterion
    AfinitorGeneric everolimus tabletsInadequate response or intolerance
    Afinitor DisperzGeneric everolimus tablets for oral suspensionInadequate response or intolerance

    Dose and Quantity Limits

    Afinitor Quantity Limit
    DrugAfinitor (everolimus tablet)
    Maximum dose10 mg per day
    Applies toSpecified Afinitor cancer and tuberous sclerosis complex indications
    Hyftor Quantity Limits
    DrugHyftor (sirolimus topical gel)
    Ages 6–11600 mg (2 cm)
    Age 12 or older800 mg (2.5 cm)

    Billing and Coding Information

    CPTHCPCS
    J9330Injection, temsirolimus (Torisel), 1 mg.
    J9331Injection, sirolimus protein-bound particles, (Fyarro) 1 mg
    Historical HCPCS codesHCPCS
    J8561Description not provided in this window.
    J7507Description not provided in this window.
    J7520Description not provided in this window.
    J9330Description not provided in this window.
    J7527Description not provided in this window.
    Historical HCPCS codesHCPCS
    J3490Description not provided in this window.
    J3590Description not provided in this window.
    C9091Description not provided in this window.
    J9331Description not provided in this window.
    Afinitor Dose
    MedicationAfinitor (everolimus tablet)
    Limit10 mg per day
    UseApplies where specified in the coverage criteria for cancer and TSC indications
    Hyftor Dose: Ages 6–11
    MedicationHyftor (sirolimus topical gel)
    Age groupIndividuals 6–11 years of age
    Dose limit

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization: Up to 6 Months

    Initial authorization for drugs listed in this policy may be approved for up to 6 months.

    Prior Authorization

    Reauthorization: Up to 12 Months

    Reauthorization may be approved for up to 12 months when the applicable drug-specific coverage criteria continue to be met and chart notes demonstrate that the individual continues to show a positive clinical response to therapy.

    Note

    Follow FDA Dosage and Administration

    Ensure the requested medication is prescribed and administered in accordance with the product's current FDA Dosage and Administration prescribing information.

    Policy Background

    mTOR is a serine/threonine protein kinase that regulates signaling involved in cell growth, proliferation, survival, protein synthesis, and angiogenesis. Dysregulation of the mTOR pathway occurs in multiple cancers, including renal cell carcinoma. mTOR inhibitors interrupt signaling involved in tumor-cell and blood-vessel growth; certain mTOR-pathway drugs are also used as immunosuppressants to prevent organ-transplant rejection.

    Clinical Terms and Abbreviations

    mTOR
    Full nameMammalian target of rapamycin
    Alternate namesMechanistic target of rapamycin; FK506 binding protein 12-rapamycin associated protein 1 (FRAP1)
    Biologic typeA serine/threonine protein kinase encoded by the FRAP1 gene
    TSC
    Full nameTuberous sclerosis complex
    Associated conditionsSubependymal giant cell astrocytoma, partial-onset seizures, renal angiomyolipoma, and facial angiofibroma
    Policy relevance
    Policy Summary
    PayerPremera Bluecross
    PolicyUse of mTOR Kinase Inhibitors in Cancer and Rare Diseases
    Policy CodePolicy N/A
    Change TypeModified
    Effective DateSep 1, 2026
    Last ReviewAug 10, 2026
    Next Review DateN/A
    Key ActionSubmit medical records documenting that medical-necessity criteria are met, including the diagnosis, relevant history, physical evaluation, and medication history.
    SourceLink
    On This Page
    Covered Drugs and IndicationsInitial Authorization RequirementsReauthorization RequirementsRequired Generic Product TrialsDose and Quantity LimitsBilling and Coding InformationAuthorization and Documentation RequirementsPolicy BackgroundClinical Terms and Abbreviations
  1. Adult with TSC-associated renal angiomyolipoma that does not require immediate surgery.
  2. Adult or pediatric individual aged 1 year or older with TSC-associated SEGA requiring therapeutic intervention but not curatively resectable.Age 1 year or older
  3. Drug-specific requirements

    • The individual has tried generic everolimus tablet and had an inadequate response or intolerance.
    • The dose is limited to 10 mg per day where specified.10 mg/day maximum
  4. Afinitor Disperz initial therapy

    Afinitor Disperz initial therapy may be considered when all of the following are met:

    ALL of the following

    • ONE TSC indication

      • TSC-associated SEGA requiring therapeutic intervention but not curatively resectable in an adult or pediatric individual aged 1 year or older.Age 1 year or older
      • TSC-associated partial-onset seizures in an adult or pediatric individual aged 2 years or older.Age 2 years or older
    • The individual has tried generic everolimus tablet for oral suspension and had an inadequate response or intolerance.

    Hyftor, Fyarro, and Torisel initial therapy

    Initial therapy may be considered when the applicable product-specific criterion is met:

    ONE product-specific indication

    • ALL of the following

      • Hyftor is requested for facial angiofibroma associated with TSC in an individual aged 6 years or older, using the applicable age-based dose limit.600 mg (2 cm) ages 6-11; 800 mg (2.5 cm) age 12 or older
    • ALL of the following

      • Fyarro is requested for an adult with perivascular epithelioid cell tumor (PEComa).Adult
    • ALL of the following

      • Torisel is requested for an individual with advanced renal cell carcinoma.Advanced RCC
    600 mg (2 cm)
    Hyftor Dose: Age 12 or Older
    MedicationHyftor (sirolimus topical gel)
    Age groupIndividuals 12 years of age or older
    Dose limit800 mg (2.5 cm)
    Prior Authorization

    Initial Authorization for Other Oral and Topical Drug Reviews

    For all other reviews involving oral and topical drugs listed in this policy, the initial authorization period may be approved for up to 6 months.

    Step Therapy

    Generic Everolimus Required Before Afinitor

    Before requesting brand Afinitor, document that the individual has tried generic everolimus tablet and experienced an inadequate response or intolerance.

    • Applies to Afinitor treatment for eligible advanced hormone receptor-positive, HER2-negative breast cancer; metastatic endometrial carcinoma used with letrozole; advanced renal cell carcinoma after sunitinib or sorafenib failure; progressive, unresectable pancreatic, gastrointestinal, or lung neuroendocrine tumors; renal angiomyolipoma associated with tuberous sclerosis complex; and subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex.
    • For covered Afinitor indications other than SEGA, the dose must also be limited to 10 mg per day.
    Step Therapy

    Generic Oral Suspension Required Before Afinitor Disperz

    Before requesting brand Afinitor Disperz, document that the individual has tried generic everolimus tablet for oral suspension and experienced an inadequate response or intolerance.

    • Applies to eligible individuals with tuberous sclerosis complex who have SEGA requiring therapeutic intervention but cannot be curatively resected, or who have TSC-associated partial-onset seizures.
    Step Therapy

    Generic Everolimus Trial Before Brand Products

    For brand products, submit documentation of the applicable generic everolimus trial before requesting coverage.

    • Afinitor requires a prior trial of generic everolimus tablet with inadequate response or intolerance.
    • Afinitor Disperz requires a prior trial of generic everolimus tablet for oral suspension with inadequate response or intolerance.
    Documentation Required

    Submit Medical Records and Office Visit Notes

    Submit the individual's medical records demonstrating that the medical-necessity criteria are met for the requested condition and medication.

    • Include office visit notes containing the diagnosis, relevant history, physical evaluation, and medication history.
    Documentation Required

    Document Ongoing Clinical Response

    For reauthorization, provide chart notes documenting that the individual continues to show a positive clinical response to therapy.

    Denial Risk

    Denial Risk: Generic Everolimus Trial or Dose Limit

    Afinitor may be denied when the required trial of generic everolimus tablet is not documented, when the individual did not have an inadequate response or intolerance to generic everolimus, or when the requested dose exceeds the applicable limit.

    • For applicable Afinitor indications, the dose is limited to 10 mg per day.
    Denial Risk

    Denial Risk: Generic Oral Suspension Trial

    Afinitor Disperz may be denied when a trial of generic everolimus tablet for oral suspension is not documented or when the individual did not have an inadequate response or intolerance to the generic oral suspension.

    Denial Risk

    Denial Risk: No Documented Ongoing Response

    Reauthorization may be denied when submitted chart notes do not document that the individual continues to show a positive clinical response to therapy.

    A condition associated with the covered uses of everolimus and topical sirolimus
    SEGA
    Full nameSubependymal giant cell astrocytoma
    Treatment criterionRequires therapeutic intervention
    Resectability criterionCannot be curatively resected
    NET
    Full nameNeuroendocrine tumors
    Origins addressedPancreatic, gastrointestinal, or lung origin
    Policy-relevant characteristicsProgressive and unresectable disease
    VHL Gene
    Full nameVon Hippel-Lindau gene
    Gene functionTumor suppressor gene implicated in the development of clear cell renal carcinoma
    Cellular relevanceIts protein product helps regulate changes in oxygen availability through control of hypoxia-inducible factor (HIF)
    mTOR Pathway
    PathwaymTOR growth and cell-signaling pathway
    Disease relevanceImplicated in tumor development, including clear cell renal cell carcinoma
    TSC associationConstitutive activation is associated with tuberous sclerosis complex
    Tuberous Sclerosis Complex
    Inheritance and biologyAn autosomal dominant genetic disorder associated with constitutive activation of mTOR
    Systemic manifestationsAffects multiple organ systems and may include benign tumors, cognitive disabilities, and behavioral problems
    Skin manifestationsFacial angiofibromas, plaques, hypomelanotic macules, ungual fibromas, and shagreen patches
    Malignant PEComa
    Full nameMalignant perivascular epithelioid cell tumor
    Study populationLocally advanced unresectable or metastatic disease
    Study requirementsCentrally confirmed pathology and measurable disease at baseline; participants had an ECOG Performance Status of 0 or 1